Skip to main content
Asbis Enterprises PLC logo

Asbis Enterprises PLC — Investor Relations & Filings

Ticker · ASB ISIN · CY1000031710 LEI · 5493003481YS4B91ZS67 WAR Wholesale and retail trade
Open in API
Filings indexed 844 across all filing types
Latest filing 2022-11-22 Share Issue/Capital Cha…
Country CY Cyprus
Listing WAR ASB

About Asbis Enterprises PLC

https://www.asbis.com/

Asbis Enterprises PLC is a value-added distributor and developer of information technology (IT), Internet of Things (IoT), and robotics products, solutions, and services. The company's portfolio includes computer hardware, software, and integrated technology solutions, alongside its own proprietary brands. A key area of focus is providing high-performance compute, storage, and networking systems tailored for demanding artificial intelligence (AI) workloads. Asbis supports a diverse range of businesses, from cloud service providers to emerging enterprises, by delivering scalable and energy-efficient infrastructure to accelerate their digital capabilities.

Recent filings

Filing Released Lang Actions
Nabycie 15,5% udziałów w spółce RSL Revolutionary Labs Ltd. - Content (EN)
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the acquisition of a significant stake (15.5%) in another company, RSL Revolutionary Labs Ltd., financed by the company's own funds. This action falls under corporate development, specifically related to mergers, acquisitions, or significant investments. Given the provided definitions, the closest fit is 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids, and by extension, significant strategic acquisitions that alter the company's structure or focus. The document is a direct announcement of a transaction, not a general regulatory filing or a report publication announcement.
2022-11-22 English
Nabycie 15,5% udziałów w spółce RSL Revolutionary Labs Ltd. - Content (PL)
M&A Activity Classification · 99% confidence The document text, written in Polish, describes ASBISc Enterprises Plc acquiring a 15.5% stake in RSL Revolutionary Labs Ltd for 700,000 EUR using its own funds. This action involves a significant investment and acquisition of shares in another company, which falls under corporate financing or M&A activity. Given the description of acquiring shares/stakes in another entity as part of a strategic move, the most appropriate classification is 'Capital/Financing Update' (CAP) or 'M&A Activity' (TAR). Since this is an acquisition of a stake rather than a full takeover bid, 'CAP' (updates on company fundraising, financing activities, or capital structure changes) is a strong fit, as is 'TAR' (Merger Proposals or Takeover Bids). However, the text explicitly details the acquisition of shares and the financing source ('środki własne Spółki' - own funds), making it a clear capital/financing transaction. I will classify it as TAR because it involves acquiring a significant stake in another company, which is a form of M&A activity, although CAP is also plausible. Given the context of acquiring a stake in a biotech firm, TAR (Merger Proposals or Takeover Bids) is slightly more specific for an acquisition event than the broader CAP category.
2022-11-22 Polish
Informacja o szacunkowych miesięcznych skonsolidowanych przychodach za październik 2022 r. - Content (EN)
Regulatory Filings Classification · 95% confidence The document is very short (663 characters) and provides an update on estimated consolidated revenues for a specific month (October 2022), explicitly referencing 'inside information' under MAR (Market Abuse Regulation). This is a preliminary disclosure of key financial metrics, not a comprehensive report (like 10-K or IR). Since it is a specific, periodic financial update announcement that doesn't fit the definition of an Earnings Release (ER, which usually covers a full quarter/period), or a Dividend Notice (DIV), it most closely aligns with a general Regulatory Filing (RNS) or potentially an Earnings Release if the context implies it's the primary result announcement for that month, although RNS is safer for MAR-based, non-standard periodic disclosures. Given the structure—a brief announcement of estimated monthly figures based on internal estimation—it functions as a mandatory regulatory disclosure that doesn't fit the other specific categories. Therefore, RNS is the most appropriate fallback.
2022-11-22 English
Informacja o szacunkowych miesięcznych skonsolidowanych przychodach za październik 2022 r. - Content (PL)
Earnings Release Classification · 100% confidence The document text is very short (506 characters) and announces estimated consolidated revenues for a specific month (October 2022) compared to the previous year. This format—a brief, preliminary announcement of key financial figures for a period shorter than a full quarter or year—aligns best with an Earnings Release (ER), which typically provides initial highlights before a full report. Although it mentions 'miesięcznych szacunkowych skonsolidowanych przychodach' (monthly estimated consolidated revenues), the closest standard SEC/regulatory filing category for initial financial highlights is ER. It is not a full report (10-K or IR), nor is it a dividend notice or management change. Given the focus on preliminary revenue figures, ER is the most appropriate classification. Q4 2022
2022-11-22 Polish
Nabycie 16% udziałów w spółce PROMED BIOSCIENCE LTD. - Content (EN)
M&A Activity Classification · 99% confidence The document explicitly announces the acquisition of a 16% stake in another company, PROMED BIOSCIENCE LTD, for EUR 800,000. This action falls under corporate transactions related to mergers, acquisitions, or significant investments. Reviewing the definitions, 'M&A Activity (Code: TAR)' is described as 'Announcements and documents related to merger proposals or takeover bids.' While this is an acquisition of shares rather than a full merger/takeover bid, it is the closest fit for a significant corporate transaction involving acquiring another entity's equity. It is not a financing event (CAP), insider dealing (DIRS), or a general regulatory filing (RNS). Therefore, TAR is the most appropriate classification.
2022-11-09 English
Nabycie 16% udziałów w spółce PROMED BIOSCIENCE LTD. - Content (PL)
M&A Activity Classification · 99% confidence The document text, written in Polish, announces that the Management Board of ASBISc Enterprises Plc has acquired a 16% stake in PROMED BIOSCIENCE LTD for 800,000 EUR using own funds. This action describes a significant corporate transaction involving the acquisition of shares in another company, which falls under the category of Mergers & Acquisitions (M&A) activity or a major investment. Based on the provided definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification for announcing the acquisition of a significant stake in another entity, even if it's not a full takeover bid.
2022-11-09 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.